Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?

Diabetologia

Volumn 56, Issue 9, 2013, Pages 1878-1883

  Nauck, M A ^a   Baranov, O ^a   Ritzel, R A ^b   Meier, J J ^c  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b Klinikum Schwabing   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

Autonomic nervous system; Gastrointestinal adverse events; Glucagon like peptide 1 (GLP 1); Glucagon like peptide 1 (GLP 1) receptor agonists; Incretin mimetics; Subcutaneous adipose tissue

Indexed keywords

ALBIGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; LIXISENATIDE; ORAL ANTIDIABETIC AGENT; SHORT ACTING DRUG; TASPOGLUTIDE;

ARTICLE; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING; WELLBEING;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS;

EID: 84881560141     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2953-6     Document Type: Article

References (33)

1. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
2. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
3. Nauck MA, Weber I, Bach I et al (1998) Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients. Diabet Med 15:937-945
4. Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W (1998) Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21:1925-1931
5. Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853-3860
6. Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
7. Nauck MA, Meier JJ (2005) Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 124 (Suppl):135-148
8. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44:1126-1131
9. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271:E458-E464
10. Nauck MA, Wollschläger D, Werner J et al (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553
11. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720-725
12. Toft-Nielsen M-B, Madsbad S, Holst JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
13. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24:720-725
14. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
15. Zander M, Christiansen A, Madsbad S, Holst JJ (2004) Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 27:1910-1914
16. Linnebjerg H, Kothare PA, Skrivanek Z et al (2006) Exenatide: effect of injection time on postprandial glucose in patients with type 2 diabetes. Diabet Med 23:240-245
17. Kolterman OG, Kim DD, Shen L et al (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62:173-181
18. Fineman MS, Bicsak TA, Shen LZ et al (2003) Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377
19. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20:411-417
20. Moretto TJ, Milton DR, Ridge TD et al (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448-1460
21. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100
22. Fehse F, Trautmann M, Holst JJ et al (2005) Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90:5991-5997
23. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS (2005) Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 37:627-632
24. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J (2006) Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes: Off J German Soc Endocrinol German Diabetes Assoc 114:417-423
25. Garber A, Henry R, Ratner R et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
26. Nauck M, Frid A, Hermansen K et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
27. Buse JB, Rosenstock J, Sesti G et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
28. Giordano A, Frontini A, Cinti S (2008) Adipose organ nerves revealed by immunohistochemistry. Methods Mol Biol 456:83-95
29. Hellström PM (2009) GLP-1: broadening the incretin concept to involve gut motility. Regul Pept 156:9-12
30. Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Göke B (2009) GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterol Motil 21(609-618):e21-e22
31. Falkén Y, Hellström PM, Holst JJ, Näslund E (2011) Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab 96:2227-2235
32. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE (2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979-1987
33. Laferrere B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709-1716